Regeneron (REGN) Receives a Hold from J.P. Morgan

J.P. Morgan analyst Cory Kasimov maintained a Hold rating on Regeneron (REGNResearch Report) on February 5. The company’s shares closed last Friday at $498.98.

According to TipRanks.com, Kasimov is a 5-star analyst with an average return of 21.2% and a 56.1% success rate. Kasimov covers the Healthcare sector, focusing on stocks such as Ultragenyx Pharmaceutical, BioMarin Pharmaceutical, and ACADIA Pharmaceuticals.

Regeneron has an analyst consensus of Strong Buy, with a price target consensus of $673.10, which is a 31.0% upside from current levels. In a report issued on February 5, Raymond James also maintained a Hold rating on the stock.

See today’s analyst top recommended stocks >>

Regeneron’s market cap is currently $53.24B and has a P/E ratio of 18.20. The company has a Price to Book ratio of 5.26.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. It product portfolio includes the following brands: EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, and Eric M. Shooter on January 8, 1988 and is headquartered in Tarrytown, NY.